紫杉醇化疗与CIK治疗对肿瘤患者免疫细胞亚型影响

Effect of paclitaxel chemotherapy and cytokine- induced killer cell therapy on immune cell subsets of tumor patients

目的分析紫杉醇化疗与CIK细胞治疗对恶性肿瘤患者免疫功能的影响,为紫杉醇化疗联合CIK细胞治疗恶性肿瘤提供理论依据。方法采集48例恶性肿瘤患者外周血,分离外周血单个核细胞,体外扩增CIK细胞,流式细胞术检测紫杉醇化疗后及CIK细胞治疗后外周血淋巴细胞亚型的变化;CIK治疗组患者行第2次CIK治疗同步紫杉醇化疗以及紫杉醇化疗组患者行第2次紫杉醇化疗同步CIK治疗其外周血淋巴细胞亚型变化。结果 CIK治疗1次后较CIK治疗前CD3+CD4+T细胞升高(P<0.05),CD4+CD25+Treg降低(P<0.01);CIK治疗患者一般情况改善;CIK治疗2次同步紫杉醇化疗后CD4+CD25+Treg低于CIK治疗1次(P<0.05);紫杉醇化疗后较化疗前CD3+CD4+T细胞升高(P<0.05),CD4+CD25+Treg降低(P<0.05);紫杉醇化疗2次同步CIK治疗较紫杉醇化疗1次CD4+CD25+Treg降低(P<0.05),CD3-CD56+NK细胞升高(P<0.05)。结论紫杉醇化疗联合CIK细胞可治疗多种恶性肿瘤患者。

Objective To analyze the effect of paclitaxel chemotherapy and CIK cell therapy on immune function ofmalignant tumor patients,and to provide theory for paclitaxel chemotherapy combined with CIK cell therapy. Methods Peripheral blood were collected from 48 malignant tumor patients and the PBMC were separated. CIK cells were amplified invitro. Flow-cytometry was performed to detect the changes of peripheral lymphocyte subsets in the malignant tumor patientsafter paclitaxel chemotherapy and CIK cell therapy. The changes of peripheral lymphocyte subsets in the malignant tumorpatients with second CIK cell therapy synchronously treated with paclitaxel chemotherapy and the patients with secondpaclitaxel chemotherapy synchronously with CIK cell therapy were analyzed. Results The proportion of CD3^＋CD4^＋T cells intumor patients after CIK cell therapy was significantly higher than that before treatment（P〈0.05）,while that of CD4^＋CD25^＋Tregcells was lower（P〈0.01）. The conditions of tumor patients were improved after CIK cell therapy. The proportion of Treg cellsafter treated with twice CIK cell therapy synchronously with paclitaxel chemotherapy was significantly lower than that treatedwith once CIK cell therapy（P〈0.05）. The proportion of CD3^＋CD4^＋T cells in tumor patients after paclitaxel chemotherapy wassignificantly higher than that before treatment（P〈0.05）,and that of CD4^＋CD25^＋Treg cells（P〈0.05）was lower; The proportion of Treg cells in patients treated with twice paclitaxel chemotherapy sychronously with CIK cell therapy was significantly lowerthan that treated with once paclitaxel chemotherapy（P〈0.05）,and that of CD3^-CD56^＋NK cells were significantly higher（P〈0.05）. Conclusions Paclitaxel chemotherapy combined with CIK cell therapy can used for treatment of a variety ofmalignant tumor patients.